1. Cell Cycle/DNA Damage Cytoskeleton Apoptosis
  2. Microtubule/Tubulin Apoptosis
  3. Docetaxel Trihydrate

Docetaxel Trihydrate  (Synonyms: 三水多烯紫杉醇; RP-56976 Trihydrate)

目录号: HY-B0011A 纯度: 99.86%
COA 产品使用指南 技术支持

Docetaxel Trihydrate (RP-56976 Trihydrate) 是一种抗肿瘤试剂,抑制微管解聚 (microtubule depolymerization) 的 IC50 值为 0.2 μM。Docetaxel Trihydrate 是紫杉醇的半合成类似物,能减弱 bcl-2bcl-xL 基因表达的影响。Docetaxel Trihydrate 阻滞G2/M细胞周期,导致细胞凋亡 (apoptosis)。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Docetaxel Trihydrate Chemical Structure

Docetaxel Trihydrate Chemical Structure

CAS No. : 148408-66-6

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥610
In-stock
100 mg ¥550
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Docetaxel Trihydrate:

MCE 顾客使用本产品发表的 107 篇科研文献

WB

    Docetaxel Trihydrate purchased from MCE. Usage Cited in: Arch Biochem Biophys. 2023 Feb 21;109551.  [Abstract]

    Docetaxel (30 nM) exhibits anti-tumor activity in parental (DU145 and PC-3) and docetaxel-resistant (DU145/DTX50 and PC-3/DTX30) cell lines by down-regulating KIF14 expression.

    Docetaxel Trihydrate purchased from MCE. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902.  [Abstract]

    Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with XRP6258 (Cab). Graphs represent the densimetric semi-quantification of western blot images.
    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule depolymerization with an IC50 value of 0.2 μM[1]. Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis[1][3].

    IC50 & Target

    Microtubule[1]

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A121 IC50
    1.2 nM
    Compound: Docetaxel
    Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure
    Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure
    [PMID: 9022794]
    A2780 IC50
    0.6 nM
    Compound: 1b
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    [PMID: 19128972]
    A2780 IC50
    0.6 nM
    Compound: Docetaxel
    Cytotoxicity against human A2780 cells by MTT assay
    Cytotoxicity against human A2780 cells by MTT assay
    [PMID: 25047938]
    A2780 IC50
    126 nM
    Compound: Docetaxel
    Antiproliferative against multidrug-resistant human A2780 cells after 72 hrs by MTT assay
    Antiproliferative against multidrug-resistant human A2780 cells after 72 hrs by MTT assay
    [PMID: 24835987]
    A2780 IC50
    290 nM
    Compound: 1b
    Cytotoxicity against p-glycoprotein expressing drug-resistant human A2780 cells after 48 hrs by MTT assay
    Cytotoxicity against p-glycoprotein expressing drug-resistant human A2780 cells after 48 hrs by MTT assay
    [PMID: 19128972]
    A2780 IC50
    33 nM
    Compound: Docetaxel
    Antiproliferative against human A2780 cells after 72 hrs by MTT assay
    Antiproliferative against human A2780 cells after 72 hrs by MTT assay
    [PMID: 24835987]
    A2780 ADR IC50
    290 nM
    Compound: Docetaxel
    Cytotoxicity against human A2780AD cells by MTT assay
    Cytotoxicity against human A2780AD cells by MTT assay
    [PMID: 25047938]
    A549 IC50
    > 1.4 μg/mL
    Compound: docetaxel
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 17624790]
    A549 IC50
    0.37 μM
    Compound: Taxotere
    Cytotoxicity against human A549 cells after 72 hrs
    Cytotoxicity against human A549 cells after 72 hrs
    [PMID: 20849074]
    A549 IC50
    1 nM
    Compound: 1b Docetaxel
    Compound was tested for its cytotoxicity by inhibiting the growth of A-549 cell line after 72 h
    Compound was tested for its cytotoxicity by inhibiting the growth of A-549 cell line after 72 h
    [PMID: 15225730]
    A549 IC50
    1 nM
    Compound: Docetaxel
    Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure
    Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure
    [PMID: 9022794]
    A549 IC50
    1 nM
    Compound: Docetaxel
    In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure
    In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure
    [PMID: 12477344]
    A549 IC50
    1 μM
    Compound: 2
    inhibitory concentration against the growth of Non-small-cell lung carcinoma A549 cell line after 72 hr of exposure
    inhibitory concentration against the growth of Non-small-cell lung carcinoma A549 cell line after 72 hr of exposure
    [PMID: 15501062]
    A549 IC50
    1.7 μM
    Compound: docetaxel
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 18226907]
    A549 IC50
    27.256 μg/mL
    Compound: Docetaxel
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    10.1007/s00044-013-0582-8
    A549 IC50
    35.2 nM
    Compound: Docetaxel
    Antiproliferative against human A549 cells after 72 hrs by MTT assay
    Antiproliferative against human A549 cells after 72 hrs by MTT assay
    [PMID: 24835987]
    A549 IC50
    4.95 x 10-4 μM
    Compound: docetaxel
    Cytotoxicity against human A549 cells after 96 hrs by microplate reader assay
    Cytotoxicity against human A549 cells after 96 hrs by microplate reader assay
    [PMID: 19133778]
    A549 IC50
    850 nM
    Compound: 2, DTX, Taxotere
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    [PMID: 24269481]
    Bel-7402 IC50
    1.9 nM
    Compound: Docetaxel
    Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    C6 IC50
    1 nM
    Compound: docetaxel
    Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test
    Cytotoxicity against Pgp deficient human LCC6 cells after 72 hrs by sulforhodamine B test
    [PMID: 18465846]
    Calu-3 IC50
    0.1 μM
    Compound: docetaxel
    Cytotoxicity against human Calu3 cells after 72 hrs by SRB assay
    Cytotoxicity against human Calu3 cells after 72 hrs by SRB assay
    [PMID: 19028425]
    COLO 205 IC50
    30.706 μg/mL
    Compound: Docetaxel
    Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
    Cytotoxicity against human COLO205 cells after 72 hrs by MTT assay
    10.1007/s00044-013-0582-8
    HCC1806 IC50
    8.4 μM
    Compound: docetaxel
    Cytotoxicity against human HCC1806 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCC1806 cells after 48 hrs by MTT assay
    [PMID: 22560315]
    HCT-116 IC50
    0.0022 μM
    Compound: 1b
    Concentration required for inhibition of 50% human colon HCT 116 cell line proliferation after 72 hr of incubation
    Concentration required for inhibition of 50% human colon HCT 116 cell line proliferation after 72 hr of incubation
    [PMID: 15537348]
    HCT-116 IC50
    0.18 nM
    Compound: 7
    Antiproliferative activity against IC95 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay
    Antiproliferative activity against IC95 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay
    [PMID: 17922005]
    HCT-116 IC50
    0.2 nM
    Compound: 7
    Antiproliferative activity against IC50 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay
    Antiproliferative activity against IC50 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay
    [PMID: 17922005]
    HCT-116 IC50
    0.23 nM
    Compound: 7
    Antiproliferative activity against human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay
    Antiproliferative activity against human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay
    [PMID: 17922005]
    HCT-116 IC50
    0.3 nM
    Compound: 7
    Antiproliferative activity against human HCT116 cells after 72 hrs by Cell titer Glo assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by Cell titer Glo assay
    [PMID: 17922005]
    HCT-116 IC50
    0.31 nM
    Compound: 7
    Antiproliferative activity against IC50 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay
    Antiproliferative activity against IC50 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay
    [PMID: 17922005]
    HCT-116 IC50
    0.35 nM
    Compound: 7
    Antiproliferative activity against 3x IC95 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay
    Antiproliferative activity against 3x IC95 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay
    [PMID: 17922005]
    HCT-116 IC50
    0.5 nM
    Compound: docetaxel
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    [PMID: 19655762]
    HCT-116 IC50
    0.52 nM
    Compound: taxotere
    Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTS assay
    [PMID: 23072299]
    HCT-116 IC50
    0.52 nM
    Compound: Taxotere
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTS assay
    [PMID: 21142180]
    HCT-116 IC50
    0.59 nM
    Compound: 7
    Antiproliferative activity against IC95 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay
    Antiproliferative activity against IC95 biaryl selected human HCT116 cells expressing Kinesin-like protein KIF11 D130V mutant after 72 hrs by Cell titer Glo assay
    [PMID: 17922005]
    HCT-116 IC50
    3 nM
    Compound: Docetaxel
    In vitro inhibition of proliferation of human colon cancer line 116 after 72 hrs incubation.
    In vitro inhibition of proliferation of human colon cancer line 116 after 72 hrs incubation.
    10.1016/S0960-894X(00)80075-X
    HCT-116 IC50
    5 x 10-2 μM
    Compound: Taxotere
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 23387796]
    HCT-116 IC50
    8.7 nM
    Compound: 7
    Antiproliferative activity against 3x IC95 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay
    Antiproliferative activity against 3x IC95 biaryl selected drug-resistant against human HCT116 cells after 72 hrs by Cell titer Glo assay
    [PMID: 17922005]
    HCT-15 IC50
    13 nM
    Compound: docetaxel
    Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
    Cytotoxicity against human HCT15 cells after 72 hrs by MTS assay
    [PMID: 19655762]
    HeLa IC50
    50.1 nM
    Compound: Docetaxel
    Antiproliferative against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative against human HeLa cells after 72 hrs by MTT assay
    [PMID: 24835987]
    Hep 3B2 IC50
    38.2 nM
    Compound: Docetaxel
    Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    HepG2 IC50
    > 100 nM
    Compound: Docetaxel
    Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    HepG2 IC50
    > 400 μM
    Compound: Taxotere
    Cytotoxicity against human HepG2 cells by SRB method
    Cytotoxicity against human HepG2 cells by SRB method
    [PMID: 18181575]
    HL-60 IC50
    0.5 nM
    Compound: taxotere
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay
    Cytotoxicity against human HL60 cells incubated for 72 hrs by MTS assay
    [PMID: 23072299]
    HL-60 IC50
    0.5 nM
    Compound: Taxotere
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    [PMID: 21142180]
    HL-60 IC50
    0.5 nM
    Compound: docetaxel
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTS assay
    [PMID: 19655762]
    HL-60 IC50
    0.52 μM
    Compound: Taxotere
    Cytotoxicity against human HL60 cells after 72 hrs
    Cytotoxicity against human HL60 cells after 72 hrs
    [PMID: 20849074]
    HL-60 IC50
    531 nM
    Compound: Taxotere
    Cytotoxicity against human HL60R cells after 72 hrs by MTS assay
    Cytotoxicity against human HL60R cells after 72 hrs by MTS assay
    [PMID: 21142180]
    HT-29 IC50
    0.92 μM
    Compound: Taxotere
    Cytotoxicity against human HT-29 cells after 72 hrs
    Cytotoxicity against human HT-29 cells after 72 hrs
    [PMID: 20849074]
    HT-29 IC50
    1 nM
    Compound: docetaxel
    Cytotoxicity against human HT-29 cells after 72 hrs
    Cytotoxicity against human HT-29 cells after 72 hrs
    [PMID: 19239240]
    HT-29 IC50
    1.2 nM
    Compound: Docetaxel
    Inhibition of the growth against human Colon Carcinoma (HT-29) cell line after 72 hr exposure
    Inhibition of the growth against human Colon Carcinoma (HT-29) cell line after 72 hr exposure
    [PMID: 9022794]
    HT-29 IC50
    3.34 x 10-4 μM
    Compound: docetaxel
    Cytotoxicity against human HT-29 cells after 96 hrs by microplate reader assay
    Cytotoxicity against human HT-29 cells after 96 hrs by microplate reader assay
    [PMID: 19133778]
    Huh-7 IC50
    12.1 nM
    Compound: Docetaxel
    Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    IMR-32 IC50
    23.71 μg/mL
    Compound: Docetaxel
    Cytotoxicity against human IMR32 cells after 72 hrs by MTT assay
    Cytotoxicity against human IMR32 cells after 72 hrs by MTT assay
    10.1007/s00044-013-0582-8
    J774 ED50
    0.05 μM
    Compound: 3a (Taxotere 10-OH)
    In vitro cytotoxicity against J774.2 cells after 72 hr incubation.
    In vitro cytotoxicity against J774.2 cells after 72 hr incubation.
    10.1016/S0960-894X(01)80527-8
    K562 IC50
    > 400 μM
    Compound: Taxotere
    Cytotoxicity against human K562 cells by SRB method
    Cytotoxicity against human K562 cells by SRB method
    [PMID: 18181575]
    K562 IC50
    6.9 μg/mL
    Compound: docetaxel
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    [PMID: 17624790]
    K562 IC50
    8.5 μM
    Compound: docetaxel
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    [PMID: 18226907]
    KB IC50
    0.0001 μM
    Compound: docetaxel, 1b
    Cytotoxicity against human KB cells after 72 hrs
    Cytotoxicity against human KB cells after 72 hrs
    [PMID: 17064914]
    KB IC50
    0.0002 μM
    Compound: taxotere
    Cytotoxicity against human KB cells after 72 hrs by neutral red staining
    Cytotoxicity against human KB cells after 72 hrs by neutral red staining
    [PMID: 19053513]
    KB IC50
    0.00025 μM
    Compound: Taxotere
    Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    [PMID: 23387796]
    KB IC50
    0.0003 μM
    Compound: 1b
    Concentration required for inhibition of 50% human fibroblast KB cell line proliferation after 72 hr of incubation
    Concentration required for inhibition of 50% human fibroblast KB cell line proliferation after 72 hr of incubation
    [PMID: 15537348]
    KB IC50
    0.15 nM
    Compound: Taxotere
    Cytotoxicity against human KB cells after 72 hrs by neutral red based colorimetry assay
    Cytotoxicity against human KB cells after 72 hrs by neutral red based colorimetry assay
    [PMID: 21443172]
    KB IC50
    0.17 nM
    Compound: taxotere
    Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay
    Cytotoxicity against human KB cells incubated for 72 hrs by MTS assay
    [PMID: 23072299]
    KB IC50
    0.17 nM
    Compound: Taxotere
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    [PMID: 21142180]
    KB IC50
    0.2 nM
    Compound: docetaxel
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    Cytotoxicity against human KB cells after 72 hrs by MTS assay
    [PMID: 19655762]
    KB IC50
    0.29 μM
    Compound: Taxotere
    Cytotoxicity against human KB cells after 72 hrs
    Cytotoxicity against human KB cells after 72 hrs
    [PMID: 20849074]
    KB IC50
    0.4 nM
    Compound: Taxotere
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTS assay
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTS assay
    [PMID: 20053482]
    KB IC50
    1.14 nM
    Compound: Taxotere
    Cytotoxicity against human KB cells by SRB method
    Cytotoxicity against human KB cells by SRB method
    [PMID: 18181575]
    KB IC50
    11.6 μg/mL
    Compound: docetaxel
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    [PMID: 17624790]
    KB 3-1 CC50
    0.25 nM
    Compound: Docetaxel
    Cytotoxicity against human KB-3-1 cells after 72 hrs by MTS assay
    Cytotoxicity against human KB-3-1 cells after 72 hrs by MTS assay
    [PMID: 18485536]
    LLC-PK1 GI50
    0.17 nM
    Compound: Doc, Taxotere
    Growth inhibition of pig LLC-PK1 cells by Alamar Blue assay
    Growth inhibition of pig LLC-PK1 cells by Alamar Blue assay
    [PMID: 23956835]
    LLC-PK1 GI50
    106.6 nM
    Compound: Doc, Taxotere
    Growth inhibition of pig LLC-PK1 cells expressing MDR1 by Alamar Blue assay
    Growth inhibition of pig LLC-PK1 cells expressing MDR1 by Alamar Blue assay
    [PMID: 23956835]
    LoVo IC50
    1.97 nM
    Compound: Taxotere
    Cytotoxicity against human LoVo cells by SRB method
    Cytotoxicity against human LoVo cells by SRB method
    [PMID: 18181575]
    MCF7 IC50
    0.001 μM
    Compound: 1b
    Concentration required for inhibition of 50% human breast MCF 7 cell line proliferation after 72 hr of incubation
    Concentration required for inhibition of 50% human breast MCF 7 cell line proliferation after 72 hr of incubation
    [PMID: 15537348]
    MCF7 IC50
    0.005 μM
    Compound: DOC
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay
    [PMID: 25817774]
    MCF7 IC50
    1 nM
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    [PMID: 25047938]
    MCF7 IC50
    1 nM
    Compound: docetaxel
    Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test
    Cytotoxicity against Pgp deficient human MCF7 cells after 72 hrs by sulforhodamine B test
    [PMID: 18465846]
    MCF7 IC50
    1 nM
    Compound: docetaxel
    Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs
    Cytotoxicity against P-glycoprotein deficient wild type human MCF7 cells after 72 hrs
    [PMID: 19239240]
    MCF7 IC50
    1 nM
    Compound: 1b Docetaxel
    Compound was tested for its cytotoxicity by inhibiting the growth of MCF-7 cell line after 72 h
    Compound was tested for its cytotoxicity by inhibiting the growth of MCF-7 cell line after 72 h
    [PMID: 15225730]
    MCF7 IC50
    1 nM
    Compound: Docetaxel
    Inhibition of the growth against human mammary carcinoma (MCF-7) cell line after 72 hr exposure
    Inhibition of the growth against human mammary carcinoma (MCF-7) cell line after 72 hr exposure
    [PMID: 9022794]
    MCF7 IC50
    1 nM
    Compound: Docetaxel
    In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure
    In vitro cytotoxicity of compound against human MCF-7 (breast) cancer cell line after 72 hr of drug exposure
    [PMID: 12477344]
    MCF7 IC50
    1 nM
    Compound: Docetaxel
    Inhibitory activity against the growth of MCF-7 (human breast carcinoma) cell line after 72 hours of drug exposure
    Inhibitory activity against the growth of MCF-7 (human breast carcinoma) cell line after 72 hours of drug exposure
    [PMID: 10617084]
    MCF7 IC50
    1 μM
    Compound: 2
    inhibitory concentration against the growth of breast cancer MCF-7 cell line after 72 hr of exposure
    inhibitory concentration against the growth of breast cancer MCF-7 cell line after 72 hr of exposure
    [PMID: 15501062]
    MCF7 IC50
    11.9 μM
    Compound: docetaxel
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 22560315]
    MCF7 IC50
    139.8 μM
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells over-expressing CYP1B1 after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells over-expressing CYP1B1 after 48 hrs by MTT assay
    [PMID: 25799264]
    MCF7 IC50
    180 nM
    Compound: Docetaxel
    Antiproliferative against multidrug-resistant human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative against multidrug-resistant human MCF7 cells after 72 hrs by MTT assay
    [PMID: 24835987]
    MCF7 IC50
    215 nM
    Compound: docetaxel
    Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs
    Cytotoxicity against human MCF7 cells expressing P-glycoprotein after 72 hrs
    [PMID: 19239240]
    MCF7 IC50
    235 nM
    Compound: Docetaxel
    Inhibitory activity against the growth of MCF-7R ( multi drug resistant human breast carcinoma) cell line after 72 hours of drug exposure
    Inhibitory activity against the growth of MCF-7R ( multi drug resistant human breast carcinoma) cell line after 72 hours of drug exposure
    [PMID: 10617084]
    MCF7 IC50
    27.6 μM
    Compound: Docetaxel
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 25799264]
    MCF7 IC50
    3.3 μg/mL
    Compound: docetaxel
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    [PMID: 17624790]
    MCF7 IC50
    38.53 nM
    Compound: Docetaxel
    Antiproliferative against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative against human MCF7 cells after 72 hrs by MTT assay
    [PMID: 24835987]
    MCF7 IC50
    4 μM
    Compound: docetaxel
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    [PMID: 18226907]
    MCF7R IC50
    235 nM
    Compound: Docetaxel
    Cytotoxicity against human MCF7/R cells by MTT assay
    Cytotoxicity against human MCF7/R cells by MTT assay
    [PMID: 25047938]
    MCF7R IC50
    235 nM
    Compound: Docetaxel
    Inhibition of the growth against human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line after 72 hr exposure
    Inhibition of the growth against human mammary carcinoma 180 fold resistant to doxorubicin (MCF-7-R) cell line after 72 hr exposure
    [PMID: 9022794]
    MDA-MB-231 IC50
    0.018 nM
    Compound: Taxotere
    Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay
    Cytotoxicity against human MDA231 cells after 72 hrs by MTS assay
    [PMID: 21142180]
    MDA-MB-231 IC50
    1 nM
    Compound: DTX
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 24564494]
    MDA-MB-435 IC50
    0.25 nM
    Compound: Taxotere
    Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay
    Cytotoxicity against human MDA435 cells after 72 hrs by MTS assay
    [PMID: 21142180]
    MHCC97H IC50
    22.4 nM
    Compound: Docetaxel
    Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    NCI/ADR-RES GI50
    196 nM
    Compound: Doc, Taxotere
    Growth inhibition of P-gp expressing human NCI-ADR-RES cells by Alamar Blue assay
    Growth inhibition of P-gp expressing human NCI-ADR-RES cells by Alamar Blue assay
    [PMID: 23956835]
    NCI/ADR-RES IC50
    235 nM
    Compound: Docetaxel
    In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure
    In vitro cytotoxicity of compound against human MCF-7-MDR (breast) cancer cell line after 72 hr of drug exposure
    [PMID: 12477344]
    NCI/ADR-RES IC50
    5.18 μM
    Compound: DOC
    Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay
    Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay
    [PMID: 25817774]
    NCI-H460 IC50
    0.0097 μM
    Compound: docetaxel
    Cytotoxicity against human NCI-H460 cells after 72 hrs by SRB assay
    Cytotoxicity against human NCI-H460 cells after 72 hrs by SRB assay
    [PMID: 19028425]
    OVCAR-8 GI50
    0.5 nM
    Compound: Doc, Taxotere
    Growth inhibition of human OVCAR8 cells by Alamar Blue assay
    Growth inhibition of human OVCAR8 cells by Alamar Blue assay
    [PMID: 23956835]
    P388 GI50
    1.62 ng/mL
    Compound: 2
    Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against mouse leukemia P388
    Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against mouse leukemia P388
    10.1016/S0960-894X(97)10128-7
    P388 GI50
    6.74 ng/mL
    Compound: 2 (Docetaxel)
    Concentration required to inhibit the growth of mouse leukemia (P388) cell lines by 50% on 72 h continuous exposure
    Concentration required to inhibit the growth of mouse leukemia (P388) cell lines by 50% on 72 h continuous exposure
    [PMID: 9871592]
    PC-12 GI50
    19.1 ng/mL
    Compound: 2
    Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against human lung cancer cell line PC-12
    Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against human lung cancer cell line PC-12
    10.1016/S0960-894X(97)10128-7
    PC-12 GI50
    42.2 ng/mL
    Compound: 2 (Docetaxel)
    Concentration required to obtain half of the maximal inhibition for cell growth in human non-small cell lung cancer cell line(PC-12) was determined by using MTT assay when the cells were exposed to compound for 72 hr
    Concentration required to obtain half of the maximal inhibition for cell growth in human non-small cell lung cancer cell line(PC-12) was determined by using MTT assay when the cells were exposed to compound for 72 hr
    [PMID: 12270153]
    PC-12 GI50
    53.4 ng/mL
    Compound: 2 (Docetaxel)
    Concentration required to inhibit the growth of human lung cancer (PC-12)cell lines by 50% on 72 hr continuous exposure
    Concentration required to inhibit the growth of human lung cancer (PC-12)cell lines by 50% on 72 hr continuous exposure
    [PMID: 9871592]
    PC-3 IC50
    1.4 nM
    Compound: Taxotere
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTS assay
    [PMID: 21142180]
    PC-3 GI50
    2.5 nM
    Compound: Doc, Taxotere
    Growth inhibition of human PC3 cells after 72 hrs by Alamar Blue assay
    Growth inhibition of human PC3 cells after 72 hrs by Alamar Blue assay
    [PMID: 23956835]
    PC-3 GI50
    54 nM
    Compound: Doc, Taxotere
    Growth inhibition of P-gp expressing docetaxel-resistant human PC3 cells after 72 hrs by Alamar Blue assay
    Growth inhibition of P-gp expressing docetaxel-resistant human PC3 cells after 72 hrs by Alamar Blue assay
    [PMID: 23956835]
    PC-3 IC50
    54.8 μM
    Compound: docetaxel
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    [PMID: 18226907]
    PC-6 GI50
    1.13 ng/mL
    Compound: 2 (Docetaxel)
    Concentration required to inhibit the growth of human lung cancer (PC-6)cell lines by 50% on 72 hr continuous exposure
    Concentration required to inhibit the growth of human lung cancer (PC-6)cell lines by 50% on 72 hr continuous exposure
    [PMID: 9871592]
    PC-6 GI50
    1.16 ng/mL
    Compound: 2
    Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against human lung cancer cell line PC-6
    Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against human lung cancer cell line PC-6
    10.1016/S0960-894X(97)10128-7
    PC-6 GI50
    1.48 ng/mL
    Compound: 2 (Docetaxel)
    Concentration required to obtain half of the maximal inhibition for cell growth in human small cell lung cancer(PC-6) was determined by using MTT assay when the cells were exposed to compound for 72 hr
    Concentration required to obtain half of the maximal inhibition for cell growth in human small cell lung cancer(PC-6) was determined by using MTT assay when the cells were exposed to compound for 72 hr
    [PMID: 12270153]
    PC-6 GI50
    135 ng/mL
    Compound: 2 (Docetaxel)
    Concentration required to obtain half of the maximal inhibition for cell growth in vincristine-resistant cell line expressing P-glycoprotein (PC-6/VCR29-9) was determined by using MTT assay when the cells were exposed to compound for 72 hr
    Concentration required to obtain half of the maximal inhibition for cell growth in vincristine-resistant cell line expressing P-glycoprotein (PC-6/VCR29-9) was determined by using MTT assay when the cells were exposed to compound for 72 hr
    [PMID: 12270153]
    PC-6 GI50
    173 ng/mL
    Compound: 2
    Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against vincristine resistant cancer cell line PC-6/VCR
    Compound was tested for growth inhibitory activity after 72 hr of continuous exposure against vincristine resistant cancer cell line PC-6/VCR
    10.1016/S0960-894X(97)10128-7
    PLC-PRF-5 IC50
    16.7 nM
    Compound: Docetaxel
    Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    SGC-7901 IC50
    0.0084 μM
    Compound: docetaxel
    Cytotoxicity against human SGC7901 cells after 72 hrs by SRB assay
    Cytotoxicity against human SGC7901 cells after 72 hrs by SRB assay
    [PMID: 19028425]
    SK-OV-3 IC50
    0.51 nM
    Compound: Taxotere
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by MTS assay
    [PMID: 21142180]
    SK-OV-3 IC50
    3.4 nM
    Compound: Docetaxel
    Cytotoxicity against human SKOV3 cells after 72 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells after 72 hrs by SRB assay
    [PMID: 18524425]
    SK-OV-3 IC50
    5 nM
    Compound: 2, DTX, Taxotere
    Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay
    [PMID: 24269481]
    SMMC-7721 IC50
    2 nM
    Compound: Docetaxel
    Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    SNU-182 IC50
    39.2 nM
    Compound: Docetaxel
    Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    SNU-387 IC50
    4.3 nM
    Compound: Docetaxel
    Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    SNU-398 IC50
    17.6 nM
    Compound: Docetaxel
    Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    SNU-423 IC50
    10.8 nM
    Compound: Docetaxel
    Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    SNU-449 IC50
    > 100 nM
    Compound: Docetaxel
    Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    SNU-475 IC50
    20.5 nM
    Compound: Docetaxel
    Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay
    Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay
    [PMID: 22320354]
    U-87MG ATCC IC50
    20.72 μg/mL
    Compound: Docetaxel
    Cytotoxicity against human U87 cells after 72 hrs by MTT assay
    Cytotoxicity against human U87 cells after 72 hrs by MTT assay
    10.1007/s00044-013-0582-8
    WI-38 IC50
    > 10 μM
    Compound: docetaxel
    Cytotoxicity against human WI38 cells after 72 hrs by SRB assay
    Cytotoxicity against human WI38 cells after 72 hrs by SRB assay
    [PMID: 19028425]
    体外研究
    (In Vitro)

    Docetaxel Trihydrate (RP-56976 Trihydrate) 和 Glufosfamide (GLU) 的单一和联合处理以剂量依赖的方式影响细胞活力。GLU在PC-3和LNCaP细胞中的IC50分别为70±4 μM和86.8±8 μM;分别。同时,在 PC-3 和 LNCaP 细胞中,单用 Docetaxel 的 IC50 分别为 3.08±0.4 nM 和 1.46±0.2 nM。GLU 与 Docetaxel 联合处理,使得在 PC-3 和 LNCaP 细胞中的 IC50 值分别降低至 2.7±0.1 nM 和 0.75±0.3 nM;分别[1]。NCI-H460 对 Docetaxel 的 IC50 在 24 小时时为 116 nM,在 72 小时时为 30 nM。根据 DTP 数据搜索中报告的数据,NCI-60 细胞板对多西紫杉醇的平均 IC50 为 14-34 nM[2]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    体内研究
    (In Vivo)

    在雌性小鼠中,Docetaxel Trihydrate (RP-56976 Trihydrate) 在光照 14 小时 (HALO) 组中诱导的肠细胞凋亡明显大于 2-HALO 组。Bax 表达在 2-HALO 组中经多西紫杉醇处理后显著升高,但在 14-HALO 组中没有。另一方面,多西他赛在 14-HALO 组中显著升高了裂解的 Caspase-3 表达,但在 2-HALO 组中没有。此外,多西紫杉醇显著降低 14-HALO 组中的survivin蛋白表达,但不降低 2-HALO 组中的存活蛋白表达。多西紫杉醇处理的14-HALO组中survivin的表达水平明显低于药物处理的2-HALO组[3]。胡椒碱 (PIP) 通过静脉推注以 3.5 mg/kg 给药,通过口服给药以 35 mg/kg 和 3.5 mg/kg 给药,而多西紫杉醇 (DOX) 以 7 mg/kg 静脉给药给 Sprague-Daley 大鼠。在 Sprague-Dawley 大鼠中通过口服给药 35 mg/kg 的 PIP 和通过静脉推注给药 7 mg/kg 的多西他赛共同给药。PIP 和多西紫杉醇的联合使用导致它们体内暴露的协同增加[4]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    分子量

    861.93

    Formula

    C43H59NO17

    CAS 号
    性状

    固体

    颜色

    White to off-white

    中文名称

    三水多西紫杉醇

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性数据
    细胞实验: 

    DMSO 中的溶解度 : 250 mg/mL (290.05 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

    Ethanol 中的溶解度 : 50 mg/mL (58.01 mM; 超声助溶)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.1602 mL 5.8009 mL 11.6019 mL
    5 mM 0.2320 mL 1.1602 mL 2.3204 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% EtOH    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (2.90 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% EtOH    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (2.90 mM); 澄清溶液

      此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    请输入您的动物体内配方组成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
    您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
    连续给药周期超过半月以上,请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.92%

    参考文献
    Cell Assay
    [1]

    Single-drug concentration-response curves are assessed. Seeding is done at a density of 2,000 cells/well for PC-3 and LNCaP, in 96-well plates. Cells are treated with each single drug and their combination for 72 h at different drug concentrations. Docetaxel is used at concentrations of 0.1-1,000 nM. GLU is used at concentrations of 0.1-300 µm. Cytotoxicity is assessed at the end of drug exposure using SRB assay. Following 72 h exposure the cells are fixed with 10% trichloroacetic acid (150 µL) for 1 h at 4°C. Then, cells are stained for 10 min at room temperature with 0.4% SRB dissolved in 1% acetic acid. The plates are then air dried for 24 h and the dye is made soluble with 150 µL Tris (10 mM, PH 7.4) for 5 min on a shaker at 1,600 rpm. Absorbance is then measured at 545 nM using microplate reader. Results are expressed as the relative percentage of absorbance compared to control[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [3][4]

    Mice[3]
    Five-week-old male Balb/c mice are used. Docetaxel (0, 10, 20, 30, 40, 60, and 80 mg/kg per week) is given once a week for 3 weeks for mice. Because more than 30 mg/kg per week of Docetaxel causes body weight loss in mice, 20 mg/kg per week of Docetaxel is judged to be the maximum nontoxic dose. Docetaxel (20 mg/kg per week) is given to mice once a week for 3 weeks at one of the following different points (2, 10, 14, or 22 HALO). Seventy-two hours after the final dosing of the agent, the intestinal mucosa of the small intestine (proximal 8 cm) is removed, fixed in 20 N Mildform solution (containing 8% formaldehyde in a buffered solution), and embedded in paraffin blocks, and sections of 5 μm are put on glass slides. Apoptosis is detected using the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method, using the Apop Tag Peroxidase In Situ Apoptosis Detection Kit.
    Rats[4]
    Male Sprague-Dawley rats with body weight between 230-250 g and age between 6-7 weeks are used. About 25 SD rats are divided into five groups receiving Docetaxel (7 mg/kg, i.v.), PIP (35 mg/kg, p.o.) and their combined administration (DOX+PIP) as well as PIP (3.5 mg/kg, p.o.) and PIP (3.5 mg/kg, i.v.). A day before the drug administrations, the rats are anesthetized with an intramuscular injection of a cocktail containing 60 mg/kg ketamine and 6 mg/kg xylazine (injection volume, 0.2 mL). Right jugular vein is cannulated with a polyethylene tubing (0.5 mm ID, 1 mm) for blood collection.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    参考文献

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
    储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 1.1602 mL 5.8009 mL 11.6019 mL 29.0047 mL
    5 mM 0.2320 mL 1.1602 mL 2.3204 mL 5.8009 mL
    10 mM 0.1160 mL 0.5801 mL 1.1602 mL 2.9005 mL
    15 mM 0.0773 mL 0.3867 mL 0.7735 mL 1.9336 mL
    20 mM 0.0580 mL 0.2900 mL 0.5801 mL 1.4502 mL
    25 mM 0.0464 mL 0.2320 mL 0.4641 mL 1.1602 mL
    30 mM 0.0387 mL 0.1934 mL 0.3867 mL 0.9668 mL
    40 mM 0.0290 mL 0.1450 mL 0.2900 mL 0.7251 mL
    50 mM 0.0232 mL 0.1160 mL 0.2320 mL 0.5801 mL
    DMSO 60 mM 0.0193 mL 0.0967 mL 0.1934 mL 0.4834 mL
    80 mM 0.0145 mL 0.0725 mL 0.1450 mL 0.3626 mL
    100 mM 0.0116 mL 0.0580 mL 0.1160 mL 0.2900 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Docetaxel Trihydrate
    目录号:
    HY-B0011A
    需求量: